Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. - Wikidata - wikimedia - TriplyDB

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

http://www.wikidata.org/entity/Q37186248

about

Aberrant expression of interleukin-1β and inflammasome activation in human malignant gliomas Current vaccine trials in glioblastoma: a review A short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiforme Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma Nanoparticles for imaging and treating brain cancer EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.Genetic signature of adult gliomas and correlation with MRI features.Immunocompetent murine models for the study of glioblastoma immunotherapy Clinical applications of a peptide-based vaccine for glioblastoma.Development of an EGFRvIII specific recombinant antibody Aptamer-conjugated PEGylated quantum dots targeting epidermal growth factor receptor variant III for fluorescence imaging of glioma EGFRvIII-targeted vaccination therapy of malignant glioma.Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses.Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery.Glioma-associated antigen HEATR1 induces functional cytotoxic T lymphocytes in patients with glioma.Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy A pan-cancer analysis of alternative splicing events reveals novel tumor-associated splice variants of matriptase.Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies.Cerebral blood volume calculated by dynamic susceptibility contrast-enhanced perfusion MR imaging: preliminary correlation study with glioblastoma genetic profiles.The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.Peptide-Targeted Gold Nanoparticles for Photodynamic Therapy of Brain Cancer.The value of EGFRvIII as the target for glioma vaccines.Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies.Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma model Glioma stem cells and immunotherapy for the treatment of malignant gliomas.Prioritization schema for immunotherapy clinical trials in glioblastoma.Targeted therapies for malignant glioma: progress and potential.Genetically engineered T cells to target EGFRvIII expressing glioblastoma.New strategies to deliver anticancer drugs to brain tumors.Design and development of therapies using chimeric antigen receptor-expressing T cells

P2860

Q24810414-74A8EBDB-6921-4A08-9EFA-C64FE8F4DAC1 Q26828965-26E2AD2F-A355-4270-A673-48B13EFFB5CC Q26849375-33D00FD8-92A6-4201-8CAB-75B6E297C766 Q27691330-7C02AFF4-4959-4339-8E69-186869BE0610 Q28069424-0C153019-38B4-4AF1-9989-37BD263EB717 Q28087306-468D0DEE-1C65-414E-9789-951F3FF0D21E Q28394053-10C7AB7D-0EE9-4C68-AB67-D392F7AE6A7C Q30456087-0018ECD3-5449-494E-B971-1B3731A90526 Q33509600-33DA5345-1966-4068-BD53-FF2CE60C463E Q33574853-E5BDFB69-2EE6-48A4-8C54-9009EC3B24D7 Q33668575-706013F6-CDD4-4E07-A119-D4DDDF5BCF00 Q33711627-AD76A1CB-2568-4EF2-B051-8D4DAFB80E1A Q33734403-53168885-7D10-4034-994B-3457BEF1F3A0 Q33758459-A6B79816-FCB7-484A-B83D-A0FE019E4122 Q33923950-D1F1E093-6003-4229-A1C3-E2CB9F992894 Q33945802-0C90EF8F-F779-43AF-B62E-B7736349AFFD Q33999299-20F747A9-2BCC-4F5C-9A1B-DF851F2C9912 Q34496174-8DDA8EAF-8A96-480A-883B-9B8A81C5A465 Q34655203-54B3C958-E3EC-4376-82C9-EBB389ACFFCE Q34744875-1554DE86-AB4D-47F6-9715-B940F8FA6DC0 Q34902490-6C8D69E9-20A3-4BA4-9625-A2C238589AA4 Q34950060-E1063492-E96D-4A92-992A-4C68DFA09BCD Q34971940-40E16D4B-AA77-4649-A02D-4CB6AF3CA3A4 Q35000726-3409C670-51FC-4C98-A39C-D766AD6FF091 Q35285859-2E79CC72-366E-429F-83FA-417DBB6B6C85 Q35527165-53B8A553-F25A-4564-A110-81E9D19094D6 Q35624110-B9ECF6FF-F860-4CFF-AD13-ED96D0E84B89 Q35627573-4D5BB32F-1CDC-4816-9198-C9C7C981B554 Q35914541-1E4E6643-D77E-4117-880B-F7D1B962D1FF Q35999648-4C6C0B2B-4279-43CA-A76C-3CD91C75C25E Q36280796-4323FFE6-2E21-4FF6-BE67-FF98AB35EE65 Q36321176-4EB96690-8549-4CFE-9A65-8D39BB4BB981 Q36345439-8D085EA3-173A-49D8-AC88-C60C0242F4DE Q36494531-68318FE6-E41A-46D9-A6DF-415A37971C6D Q36898699-76942D3B-C1DB-4A41-9608-A1A475D7D969 Q37078999-CB7AAC76-399F-42D5-A458-74640B710098 Q37159549-23238098-CE8A-426B-95DC-0E2C639DC42D Q37316117-98B7C8EA-BBB3-441A-BD42-1F0F7E23C76E Q37364700-B626AAB7-B569-46D0-B522-FF1DC343A774 Q37418289-F2F47C00-5207-4AC3-BD0F-56F5CC49BA74

P2860

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

http://www.wikidata.org/entity/Q37186248

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 June 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Tumor-specific immunotherapy t ...... atients with malignant glioma.

@en

Tumor-specific immunotherapy t ...... atients with malignant glioma.

@nl

type

label

Tumor-specific immunotherapy t ...... atients with malignant glioma.

@en

Tumor-specific immunotherapy t ...... atients with malignant glioma.

@nl

prefLabel

Tumor-specific immunotherapy t ...... atients with malignant glioma.

@en

Tumor-specific immunotherapy t ...... atients with malignant glioma.

@nl

P1433

Q37186248-BF11A7E1-081C-4B71-AD89-37EAD8BBFA08

P1476

Q37186248-C9F04014-5B88-4AF4-ADB5-B771728AE642

P2093

Q37186248-2BE77F4F-99F5-4E7D-9AC5-CCDB471112CF

Q37186248-2CE4677C-09BA-476B-8830-4EF09B535CDE

Q37186248-32C4D26C-F10F-4CFD-A245-6A58134445D2

Q37186248-FD445772-0E71-4929-8324-C4BA97D6FE90

P2860

Q37186248-015526B8-5345-487C-B90F-18FD2D1DD1D9

Q37186248-01709C58-1756-4B71-A726-DB275EAA166A

Q37186248-01922F32-DFD9-436D-AADB-CEF982854D73

Q37186248-01E2FCDC-9EC4-4A91-8F51-CCE70540FBB0

Q37186248-07EDDD4D-5170-4A26-AB4F-CEE5024726AC

Q37186248-0865E15E-5706-40B1-B13C-A2D433F82D20

Q37186248-0A6B4787-6799-4BDB-93C0-8F4C194BD168

Q37186248-0C489D83-447F-4080-B8A4-AF0939EE3E2E

Q37186248-0FB93CF0-EFF2-478D-8067-E8333A410018

Q37186248-1022F136-92F9-4D82-8531-0929BF664716

P304

Q37186248-01152B82-6C04-416B-A70A-BDA680A0803B

P31

Q37186248-61958F4E-184C-4D15-B4A1-0388098AF0CD

P356

Q37186248-D60ECDDF-DBEB-4E9F-97A6-7A005349287D

P433

Q37186248-DEE61EA4-E739-4862-84B6-44FA77E41E18

P478

Q37186248-020268FE-E3F9-4D72-A107-C69F3C6BC08D

P50

Q37186248-3B239C9C-29CD-4E77-97C3-EA61B22D6C3A

P577

Q37186248-AF664423-AB86-4125-A85E-096985EECB3A

P5875

Q37186248-C57606D4-20A9-41E1-AA3F-741BF334970B

P698

Q37186248-CDE21AEC-AA8C-484B-8FDF-68A5E266B628

P921

Q37186248-5A290EEC-0DDC-4314-8888-218E360CF7F8

Q37186248-740E6996-CF25-4E88-9981-DA33B3800161

P932

Q37186248-584D4B62-DBAF-44DA-B8C9-000FFAAA9B71

P356

J.SMIM.2008.04.001

P1433

Seminars in Immunology

P1476

Tumor-specific immunotherapy t ...... atients with malignant glioma.

@en

P2093

Amy B Heimberger

http://www.w3.org/2001/XMLSchema#string

Duane A Mitchell

http://www.w3.org/2001/XMLSchema#string

Gary E Archer

http://www.w3.org/2001/XMLSchema#string

John H Sampson

http://www.w3.org/2001/XMLSchema#string

P2860

Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family

The response of autologous T cells to a human melanoma is dominated by mutated neoantigens

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Cancer immunotherapy: moving beyond current vaccines

Cancer regression in patients after transfer of genetically engineered lymphocytes

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Regulatory T cells in the control of autoimmunity: the essential role of transforming growth factor beta and interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral CD4(+)CD45RC- cells and CD4(+)CD8(-) thymocytes

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

P304

267-275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.SMIM.2008.04.001

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Darell D. Bigner

P577

2008-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5316962

http://www.w3.org/2001/XMLSchema#string

P698

18539480

http://www.w3.org/2001/XMLSchema#string

P921

P932

2633865

http://www.w3.org/2001/XMLSchema#string